|Bid||0.00 x 1200|
|Ask||0.00 x 800|
|Day's range||46.80 - 48.17|
|52-week range||26.81 - 84.83|
|Beta (5Y monthly)||1.35|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Thank you for joining us today to discuss Arrowhead's results for its fiscal 2022 third quarter ended June 30, 2022. With us today from management are president and CEO, Dr. Christopher Anzalone, who will provide an overview of the quarter; Dr. Javier San Martin, our chief medical officer, who will provide an update on our mid-and later-stage clinical pipeline; Dr. James Hamilton, our senior vice president of Discovery and Translational Medicine, who will provide an update on our earlier stage programs; and Ken Myszkowski, our chief financial officer, who will give a review of the financials.
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
The big shareholder groups in Arrowhead Pharmaceuticals, Inc. ( NASDAQ:ARWR ) have power over the company. Institutions...